Robert Karl
Investment Director / Bio-Partnering
Investment Strategy and Capital for Life-Sciences Companies
A partner of RBV Capital, Robert joint IAG in 2015 to contribute to strategic growth of the group and expand Bio-Partnering. He is heavily involved into building a diversified investment portfolio composed of early to market stage products. His interests are in biopharmaceuticals, biomedical technology and services, bioinformatics and healthcare IT, medical devices and innovative healthcare providers as well as cross-discipline companies.
IAG (Image Analysis Group)
Our next-gen platform, R&D and service divisions together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.
Image Management Platform
Real-time information, patented data analysis methodologies, flexible reporting options for all stakeholders ensure transparency of trial process and the use of the latest scientific innovation in proving efficacy of your novel treatments.
Careers
In addition to specific listed roles, we are always looking for biotech and pharma experts and enthusiasts with entrepreneurial mindset, can-do attitude and solid scientific background.